KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Debt: 2011-2022

Historic Total Debt for TherapeuticsMD (TXMD) over the last 6 years, with Sep 2022 value amounting to $93.6 million.

  • TherapeuticsMD's Total Debt fell 49.88% to $93.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $575.5 million, marking a year-over-year decrease of 32.49%. This contributed to the annual value of $188.3 million for FY2021, which is 20.79% down from last year.
  • According to the latest figures from Q3 2022, TherapeuticsMD's Total Debt is $93.6 million, which was up 3.11% from $90.8 million recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Total Debt peaked at $243.4 million during Q1 2020, and registered a low of $73.1 million during Q2 2018.
  • In the last 3 years, TherapeuticsMD's Total Debt had a median value of $187.5 million in 2021 and averaged $185.0 million.
  • As far as peak fluctuations go, TherapeuticsMD's Total Debt soared by 231.19% in 2020, and later tumbled by 51.00% in 2022.
  • Over the past 5 years, TherapeuticsMD's Total Debt (Quarterly) stood at $73.4 million in 2018, then skyrocketed by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then declined by 20.79% to $188.3 million in 2021, then plummeted by 49.88% to $93.6 million in 2022.
  • Its Total Debt was $93.6 million in Q3 2022, compared to $90.8 million in Q2 2022 and $202.9 million in Q1 2022.